Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Infliximab for the Treatment of Moderate-to-Severe Psoriasis: Response to Retreatment

C. Leonardi, A. Menter, A. Kimball, C. Guzzo. . Infliximab for the Treatment of Moderate-to-Severe Psoriasis: Response to Retreatment. 15th Congress of the European Academy of Dermatology and Venereology, Rhodes, Greece. 2006.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.